Retatrutide: The Triple‑Agonist Metabolic Enhancer
Maximize Weight Loss, Glycemic Control, and Metabolic Health
Retatrutide is an investigational peptide therapy designed to activate three critical metabolic receptors—GLP-1, GIP, and glucagon. This triple agonist approach mimics and amplifies the body’s natural metabolic signals, resulting in profound effects on fat loss, blood sugar regulation, liver health, and inflammation.
What sets Retatrutide apart is its multi-hormone mechanism, which doesn’t just suppress appetite but also increases energy expenditure, reduces visceral and liver fat, and improves overall cardiometabolic function. In clinical trials, Retatrutide has achieved some of the highest weight loss outcomes ever recorded for a non-surgical treatment, while also addressing underlying drivers of metabolic disease.
Retatrutide is a multi-receptor agonist, meaning it activates three hormone pathways simultaneously:
- GLP-1 (Glucagon-like Peptide-1): Promotes satiety, slows gastric emptying, and enhances glucose-stimulated insulin secretion.
- GIP (Glucose-dependent Insulinotropic Polypeptide): Enhances insulin release in response to meals and synergizes with GLP-1 to improve metabolic response.
- Glucagon Receptor: Stimulates fat oxidation, increases energy expenditure, and reduces liver fat stores.
Together, these pathways reshape the body’s energy balance, reduce food intake, burn fat stores, and improve metabolic biomarkers more effectively than single-pathway drugs.
Key Potential Benefits
- Dramatic Weight Reduction – Participants in a 48‑week Phase 2 study lost up to 24.2% of initial body weight at higher doses.
- Enhanced Glycemic Control – Significant reductions in HbA1c and fasting glucose were observed in adults with obesity ± type 2 diabetes, outperforming monotherapies.
- Liver Fat & Liver Health Support – Over 80% of participants achieved ≥70% reduction in liver fat; >85% resolved steatosis in a MASLD subgroup.
- Improved Cardiometabolic Markers – Notable drops in blood pressure, triglycerides (‑40%+), LDL, and inflammatory biomarkers.
- Favorable Body Composition – Retains lean mass while reducing fat mass, based on recent body‑composition data.
- Convenient Weekly Dosing – Long half-life (~6 days) allows comfortable once‑weekly subcutaneous injections.
Research Sources
- Triple–Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial
- Retatrutide in patients with obesity and MASLD
- Body composition outcomes of Retatrutide in patients with obesity
- Retatrutide in type 2 diabetes – efficacy and glucose response
- Sub-analysis of the Phase 2 trial in Nature Medicine
- ClinicalTrials.gov: Ongoing global studies on weight loss, cardiovascular risk, and diabetes outcomes
Technical Information
CAS Number: | 2381089-83-2 |
PubChem CID: | 171390338 |
Formula: | C221H342N46O68 |
Synonyms: | Retatrutide, 2381089-83-2, EX-A7826E, GTPL13769 |